+1-888-308-5802      . .

Roche’s Tecentriq bags priority review for treating advanced NSCLC

Author : Pankaj Singh | Published Date : 2020-02-20 

Roche’s Tecentriq bags priority review for treating advanced NSCLC

Swiss multinational pharmaceutical company, Roche has recently revealed that the U.S. FDA has acknowledged its sBLA (supplemental Biologics License Application) and approved Priority Review for Tecentriq® (atezolizumab) as an initial monotherapy for patients suffering from advanced NSCLC (non-squamous and squamous non-small cell lung cancer) without ALK mutations with elevated PD-L1 expression or EGFR. Reportedly, the FDA is anticipated to come to a decision by June 19, 2020.

According to reliable sources, this sBLA is centered around the findings from the Phase III IMpower110 trial, which demonstrated that Tecentriq monotherapy enhanced OS (overall survival) by 7.1 months when equated to chemotherapy in patients with extreme PD-L1 expression. Tecentriq’s safety profile seemed to be coherent with its known safety profile, with no additional safety signals being detected.

Speaking on the move, Levi Garraway, M.D., Ph.D., Head of Global Product Development and Chief Medical Officer, Roche, said that revisiting the IMpower110 trial, Tecentriq solely established a noteworthy improvement in OS when compared to chemotherapy for newly diagnosed NSCLC patients.

Additionally, the company is closely working with the FDA to release its chemotherapy-free alternative for all NSCLC patients as soon as possible.

Prior to this news, Roche had made headlines when the China National Medical Products Administration (NMPA) granted approval Tecentriq®, in association with chemotherapy ( etoposide and carboplatin), for the initial therapy of patients with ES-SCLC (extensive-stage small cell lung cancer).

Commenting on which, Garraway added that small cell lung cancer is a crucial segment with huge unmet needs in China. Besides, there haven’t been any major advances in this sector until now.

With this consent, Tecentriq would become the first-ever cancer immunotherapy to be accessible in China for the first-line therapy of ES-SCLC. This would come as an important and swift leap for patients, in terms of medical progression, who suffer from this chronic disease.

Source Credit: http://www.globenewswire.com/news-release/2020/02/19/1986747/0/en/FDA-grants-priority-review-to-Roche-s-Tecentriq-monotherapy-as-first-line-treatment-of-certain-people-with-advanced-non-small-cell-lung-cancer.html

About Author

Pankaj Singh . .

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Bayers new CEO initiates management job cuts to accelerate decision-making

Bayers new CEO initiates management job cuts to accelerate decision-making

Published Date: 2023-09-15         Author: Pankaj Singh

Bayer newly appointed CEO, Bill Anderson, has reportedly unveiled plans to streamline the companys management structure in a bid to expedite decision-making processes. This marks the first step in a broader effort to transform the embattled German company, which has been under pressure from inv... Read More>>

Smurfit Kappa in Merger Talks with WestRock worth $19 Billion

Smurfit Kappa in Merger Talks with WestRock worth $19 Billion

Published Date: 2023-09-08         Author: Pankaj Singh

Smurfit Kappa, a prominent player in the packaging industry, is reportedly engaged in merger discussions with its US counterpart, WestRock. This prospective merger has the potential to create a cardboard box-making powerhouse boasting a market value approaching $19 billion (€17.8 billion). Furt... Read More>>

RBC plans job cuts to take on anticipated economic softening

RBC plans job cuts to take on anticipated economic softening

Published Date: 2023-08-25         Author: Pankaj Singh

The Royal Bank of Canada is reportedly planning to reduce its workforce by approximately 1,800 jobs as part of cost-cutting measures, on account of the anticipated upcoming economic landscape. This decision comes after the country's largest bank surpassed analysts' predictions for the third ... Read More>>

© 2024 Fractovia. All Rights Reserved